Extravasation of monoclonal antibodies commonly used in oncology: Classification, management and the role of the pharmacist.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Bauters T
- Clottens N
Abstract
INTRODUCTION: Extravasation by conventional cytotoxics has been well documented. While monoclonal antibodies are not considered to have the necrotic potential of some cytotoxic medicines, they require appropriate management in case of extravasation. However, fewer data are available on their classification and appropriate management when extravasation occurs. As monoclonal antibodies are being more commonly used in current daily oncology practice, this is an issue that cannot be ignored. METHODS: A scientific literature review on PubMed was conducted. All findings were critically appraised independently by 6 clinical pharmacists in order to provide a classification according to the extravasation hazard. RESULTS: A classification of non-conjugated and conjugated monoclonal antibodies according to extravasation hazard has been elaborated for different molecules frequently used in oncology. In addition, general management, in case extravasation of monoclonal antibodies occurs, has been proposed and the role of the pharmacist in the extravasation process has been described. CONCLUSION: A classification of hazard extent of extravasation of monoclonal antibodies with concurrent management based on literature data and expert consensus has been elaborated. In addition, the role of the oncology pharmacist is crucial in terms of follow-up and documentation of the extravasated monoclonal antibody and management is described.
Datos de la publicación
- ISSN/ISSNe:
- 1078-1552, 1477-092X
- Tipo:
- Article
- Páginas:
- 488-492
- PubMed:
- 37226295
- Factor de Impacto:
- 0,374 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners SAGE Publications
Documentos
- No hay documentos
Filiaciones
Keywords
- Extravasation; monoclonal antibodies; role of pharmacist
Proyectos y Estudios Clínicos
EVALUACIÓN DE EFICACIA Y TOXICIDAD DE LA TERAPIA ANTIFÚNGICA CON VORICONAZOL EN BASE A ESTUDIOS FARMACOGENÉTICOS Y ANÁLISIS FARMACOCINÉTICOS-FARMACODINÁMICOS.
Investigador Principal: VIRGINIA BOSÓ RIBELLES
MJL-VOR-2016-01 . 2018
IDENTIFICACIÓN DE FACTORES CLÍNICOS, MOLECULARES Y RADIOLÓGICOS PREDICTORES DE RESPUESTA AL TRATAMIENTO CON BEVACIZUMAB EN PACIENTES CON GLIOMAS DE ALTO GRADO: BEVA-GLIO.
Investigador Principal: ANA ALEJANDRA GARCÍA ROBLES
AGR-BEV-2018-01 . 2018
EFICACIA Y SEGURIDAD A LA QUIMIOTERAPIA INTRAPERITONEAL EN CÁNCER DE OVARIO EN ESTADIO III TRAS CIRUGÍA CITORREDUCTORA.
Investigador Principal: OCTAVIO ANTONIO BALLESTA LÓPEZ
OBL-PAC-2019-01 . 2020
Programa Educacional y de Apoyo a Pacientes con Hemofilia para la Mejora de la Adherencia.
Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS
OATPEHEM2102 . 2023
RESULTADOS EN SALUD DE PEMBROLIZUMAB EN PRIMERA LÍNEA EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO METASTÁSICO.
Investigador Principal: ASUNCIÓN ALBERT MARÍ
FEF-PEM-2020-01 . 2022
Estudio observacional para evaluar la adherencia a TREMFYA® (guselkumab) en la práctica clínica en pacientes con psoriasis moderada a grave.
Investigador Principal: EMILIO MONTE BOQUET
CNTO1959PSO4024 . 2023
Efectividad y seguridad de Nivolumab en pacientes con Linfoma de Hodgkin clásico en recaída o refractario. Datos en vida real.
Investigador Principal: LAURA LORENTE FERNANDEZ
NIVOLH-01 . 2023
Cita
Bauters T,Clottens N,ALBERT MA. Extravasation of monoclonal antibodies commonly used in oncology: Classification, management and the role of the pharmacist. J Oncol Pharm Pract. 2023. 30. (3):p. 488-492. IF:1,000. (4).